-
Guideline on adjustment for baseline covariates in clinical trials | Reason for using stratified designs - https://ecs.page.link/ndwtZ
#Regulatory#Pharma#MedicalDevice#Biotech#FDA#Health#LifeSciences#ClinicalTrails#Biosimilars#Clinicallife#Biostatisticspic.twitter.com/5fi2v7Ic3z
-
Hodge-podge spin out by
$MCK includes#biosimilars marketing org for drugs licensed from Samsung Bioepis. Would make sense to do another spin out creating pure#biosimilars co and then buy$CHRS with better marketing org. Eliminate duplicate R&D and fill each other’s gaps -
.
@breastoncdoc of@UPMCHillmanCC discusses the emergence of#biosimilars in oncology and how he anticipates they will change the paradigm http://ow.ly/CY0l50yeL2m -
BREAKING:
@Merck announces#biosimilars spin-off company + new HQ in New Jersey near parent campus. 75% of new co.’s sales expected to come from outside U.S. & involve 10k-11k employees under direction of new spin-off CEO Kevin Ali, a 30-yr. Merck veteran. pic.twitter.com/bgoEQiStUL
-
How much does your state save? In 2018, generic prescription medicines saved
#Indiana $6.4B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved: https://rxsavingsmap.org/#GRxBiosimsSavingsReport#generics#biosimilars pic.twitter.com/byuXQ0LXww
-
Lack of penetration of infliximab
#biosimilars: Is this news to anyone? https://bit.ly/2UpPfuN@pfizer@JanssenGlobal#remicade#inflectra#renflexis -
$MCK just did a spin out of hodge-podge product lines including#biosimilars licensed from Samsung Bioepis. Would make sense for$MRK to do another spinout of#biosimilars then do a M&E with$CHRS with better marketing org. Eliminate duplicate R&D. Also each fills gaps in other -
check out my latest post on
$MCK spin out of hodge-podge product lines including#biosimilars licensed from Samsung Bioepis. Would make sense for$MRK to do another spinout of#biosimilars then do a M&E with$CHRS with better marketing org. Eliminate duplicate R&D. -
$MCK -- new hodge-podge spin out includes#biosimilars marketing org for drugs licensed from Samsung Bioepis. Would make sense for further spin out of pure#biosimilars co and buy$CHRS with better marketing org. Eliminate duplicate R&D (even I can make a bull case for$CHRS) -
@Coherus_Bio has a set back on Lucentis biosimilar: BLA submission withdrawn after FDA concerns over manufacturing.#biosimilars$CHRShttps://twitter.com/larrywabrams/status/1224911334787047424 … -
#Biosimilars Enter US Market, Poised to Impact#Cancer Treatment@breastoncdoc@UPMCHillmanCC http://ow.ly/Sm9R50yepLJ -
Interesting...business and property concerns but I wonder how they will address bioequivalence challenges....insights welcome as I'm definitely not well-versed!
#biologics#biosimilars#FDA#FTC#competition#marketaccess https://lnkd.in/epxfMuV -
Clinical Data Management Steps and Processes | JLI Blog -https://ecs.page.link/CxUjs
#ClinicalData#Regulatory#Pharma#MedicalDevice#Biotech#FDA#Health#LifeSciences#ClinicalTrails#Oncology#Biosimilars#ClinicaLlife#RegulatoryMedicalWriting#ClinicalDevelopment -
Check out my recent article in Pharmaceutical Technology on the potential impact of
#biosimilars in 2020.#marketaccess#drugpricing#oncology#drugdevelopment#immunologyhttps://lnkd.in/edHQne2 -
.
@Merck to spin-off#WomensHealth &#Biosimilars into unnamed company to achieve $1.5B in operating efficiencies by 2024 NewCo also to snag legacy brands in#dermatology,#pain,#respiratory & some#cardiovascular markets https://merck.unleashinggrowthpotential.com/#pharma#biopharmapic.twitter.com/pgnM0xVqqA
-
The FTC and the New York Attorney General have sued Vyera Pharmaceuticals and two of its executives for antitrust law violations. Read about the challenges of bringing biosimilars to market by clicking here: https://hubs.ly/H0mTNz70
#FTC#biosimilars#MoginRubin#Daraprimpic.twitter.com/uFgY14NW0N
-
Dr. Sarah Yim, Director of the Office of
@US_FDA's OTBB, hopes to see comparable robustness of the U.S.#biosimilars market to the European market in 10 years https://pink.pharmaintelligence.informa.com/PS141542/US-FDAs-Yim-Hopes-To-See-EuropeanLike-Robustness-For-US-Biosimilars-Market-In-10-Years … -
#Biosimilars are much much harder to manufacturing than small molecule generics. Tossing off an FDA identified issue with$CHRS newbie European partner’s contract manufacturer process, however small, as “growing pains” ignores fact that patients’ lives are at stake here. -
Looking for information about
#biologics and#biosimilars? Take a peek at our#fact sheet, and learn why we advocate for patient-doctor choice

.
http://bit.ly/2txTY23 pic.twitter.com/KJuz0tenoU
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.